Breast cancer cells that overexpress HER-2/neu are more resistant to chemotherapeutic agents such as paclitaxel (Taxol) and docetaxel (Taxotere) than those that do not overexpress HER-2/neu. In previous work, we showed that the adenovirus type 5 E1A can repress HER-2/neu expression at the transcriptional level. Here we ®rst demonstrated that paclitaxel sensitivity correlates with HER-2/neu expression level in a panel of mouse ®broblasts expressing dierent levels of HER-2/ neu, and that downregulation of HER-2/neu expression by E1A sensitizes the cells to paclitaxel. To further test whether E1A can sensitize HER-2/neu-overexpressing human breast cancer cells to paclitaxel through E1A-mediated HER-2/neu repression, an adenoviral vector was used to transfer the E1A gene into two human breast cancer cell lines, MDA-MB-453 and MDA-MB-361, that overexpress HER-2/neu. After E1A delivery, we observed that HER-2/neu expression level was reduced, and cells were treated with paclitaxel. Cell proliferation assays showed a synergistic growth inhibition eect of E1A and paclitaxel. The synergistic eect was also con®rmed by soft agar colony-formation assay. Breast cancer cell lines that express low levels of HER-2/neu, MDA-MB-435 and MDA-MB-231 cells showed no synergistic growth inhibition eect when treated on the same protocols. Thus, we concluded that the adenovirus type 5 E1A gene can sensitize paclitaxel-resistant HER-2/neu-overexpressing breast cancer cells to the drug by repressing HER-2/neu expression. This in turn may have important implications for the development of a novel therapy that combines chemotherapy and gene therapy.
Introduction
The HER-2/neu gene encodes a 185-kDa transmembrane growth factor receptor (p185) with tyrosine kinase activity (Bargmann et al., 1986; Bargmann and Weinberg, 1988; Coussens et al., 1985; Schechter et al., 1985; Stern et al., 1988; Yamamoto et al., 1986) and is ampli®ed or overexpressed in approximately 30% of human breast cancers (Gusterson et al., 1992; McCann et al., 1991; Slamon et al., 1987 Slamon et al., , 1989 Toikkanen et al., 1992; van de Vijver et al., 1987) . Several reports have revealed that the overall survival and disease-free survival rates for patients with HER-2/neu-overexpressing breast cancers are signi®cantly less than for patients whose cancers do not overexpress HER-2/ neu, indicating that HER-2/neu overexpression may be a prognostic factor (Gusterson et al., 1992; McCann et al., 1991; Slamon et al., 1987 Slamon et al., , 1989 Toikkanen et al., 1992; van der Vijver et al., 1987) . Enhanced expression of the HER-2/neu gene can also increase experimental metastasis in mouse embyro ®broblasts and human lung cancer cells (Yu et al., 1992 (Yu et al., , 1994b . HER-2/neu overexpression can cause chemoresistance in some non-small-cell lung cancer cell lines (Tsai et al., 1994 (Tsai et al., , 1995 . Moreover, some HER-2/neuoverexpressing human breast cancer cell lines MDA-MB-453, MDA-MB-361, BT-474, BT-483, and SK-Br-3 are highly resistant to two chemotherapeutic drugs, paclitaxel (taxol) and docetaxel (taxotere) . All these data together may explain the poor clinical outcome for patients with HER-2/neu-overexpressing cancers.
The adenovirus type 5 E1A gene is a well-known transcriptional factor (Nevins, 1995) , whose products inhibit HER-2/neu expression in both rodent and human breast cancer cells and ovarian cancer cells through the HER-2/neu promoter with involvement of its co-activator p300 (Chen and Hung, 1997) ; this inhibition abolishes the tumorigenicity and metastatic potential induced by the HER-2/neu oncogene by repressing its expression (Yan et al., 1991; Yu et al., 1990 Yu et al., , 1993b . Currently, the E1A gene is not known to repress other epidermal growth factor receptor promoters, such as EGFR, HER-3 and HEr-4.
On the basis of this information, we have hypothesized that E1A may sensitize HER-2/neuoverexpressing human breast cancer cells to the chemotherapeutic agent paclitaxel by downregulating the expression of HER-2/neu. We designed our present experiments to test this hypothesis by using adenoviral vectors to introduce the E1A gene into cancer cells (Zhang et al., 1995) .
Results

Sensitivity to paclitaxel depends on HER-2/neu expression level
To test whether E1A could sensitize HER-2/neuoverexpressing cell lines to paclitaxel, we compared the cytotoxicity of paclitaxel against a series of stable transfectants expressing dierent levels of HER-2/neuencoded p185 proteins (Yu et al., 1993a) (Figure 1a) . The B104-1-1 cell line is an NIH3T3 derivative expressing p185 by transfection of the genomic mutation-activated rat HER-2/neu oncogene. The B.neo cell line was obtained by transfection of a neomycin-resistant selection marker gene into B104-1-1 cells. The E1A gene was cotransfected with the neomycin-resistance selection marker gene into B104-1-1 cells to generate B.E1A1 cells in which p185 expression was repressed by E1A. The B.E1A.D1 line was obtained by reexpression of p185 in B.E1A1 cells through cotransfection of a second marker gene, pSV2-hygromycin, and a HER-2/neu cDNA construct driven by the Rous sarcoma virus-long terminal repeat promoter that could not be repressed by E1A.
As shown in Figure 1b , HER-2/neu expression level's correlated very well with the paclitaxel-resistant phenotype. The B.E1A1 cell line, in which p185 is downregulated by E1A, was the most sensitive to paclitaxel (1 to 10 mM). Other cell lines, such as B104-1-1, B.neo, and B.E1A1.D1, that express a high level of p185 are much more resistant to paclitaxel. Since paclitaxel is a G 2 /M phase-speci®c inhibitor (Horwitz, 1994; Schi and Horwitz, 1980) , faster cell growth rate might contribute to the paclitaxel-sensitive phenotype. However, of all the cell lines tested, the most sensitive line, B.E1A1 was the slowest growing line (Yu et al., 1993a; ; thus, the paclitaxel sensitivity of this cell line can not be due to its growth rate. It is also worth mentioning that even though the B.E1A1.D1 cells still expressed E1A protein, their level of p185 reexpression was similar to that in B104-1-1 and B.neo cells and their paclitaxel resistance recovered to a level equivalent to that in B104-1-1 and B.neo cells. Taken together, these results suggest that the paclitaxel-resistant phenotype is most likely caused by enhanced p185 expression and that downregulation of p185 by E1A can convert a resistant phenotype into a sensitive one.
Establishment of adenoviral vector infection eciency in breast cancer cell lines
Stable transfectants of mouse embryo ®broblast cell lines were used in the above-mentioned experiment, and the results indicate that E1A can sensitize mouse embryo ®broblasts to paclitaxel. We next examined whether E1A can sensitize HER-2/neu-overexpressing human breast cancer cells to paclitaxel. We used an adenoviral vector delivery system that allows transient expression of the E1A gene at a high-infection eciency in tumor cells and that may be used for potential therapy.
Four human breast cancer cell lines were used in our study. MDA-MB-435 and MDA-MB-231 express low levels of HER-2/neu; MD-MB-453 and MDA-MB-361 express high levels. To evaluate the infection eciency of the adenovirus on these dierent lines, the lines were treated with Ad.RSVlacZ at dierent virus/tumor cell (V/T) ratios under a regular infection protocol, which contains FBS in the medium. Two days after the addition of Ad.RSVlacZ virus, cells were ®xed and stained with X-gal; virus-infected cells that express the lacZ gene can be visualized by their blue colour. The infection eciency increased proportionally with V/T ratio and was highest among the HER-2/neu-overexpressing breast cancer cell lines (Figure 2a ). An infection eciency of almost 100%, with no cytopathic eect at a V/T ratio of 200 : 1, was obtained in both MDA-MB-453 and MDA-MB-361 cells.
However, low-HER-2/neu-expressing breast cancer cell lines had low infection eciencies, only about 20 ± 30% even at a V/T ratio of 400 : 1. We hypothesized that this may have been partially due to the cells' rapid growth rate resulting in a dilution of the gene expression, as MDA-MB-435 and MDA-MB-231 grow faster than MDA-MB-453 and MDA-MB-361 in the presence of serum. To overcome this problem, FBS was depleted from the culture medium during the viral infection stage, a strategy we called the serum-depleted infection protocol. This resulted in infection eciencies over 95% in cell lines MDA-MB-435 ( Figure 2b ) and MDA-MB-231 (data not shown) at a V/T ratio of 400 : 1. We ®rst examined the correlation of E1A gene expression and downregulation of HER-2/neu expression after adenoviral vector infection. The HER-2/neuoverexpressing breast cancer cell line MDA-MB-453 was treated with Ad.E1A(+) or Ad.E1A (7) for 48 h at dierent V/T ratios (50 : 1, 100 : 1, and 200 : 1). Within 48 h, the cells expressed E1A protein in a dosedependent manner, as determined by Western blot analysis with the anti-E1A antibody m58 (Figure 3 ). Ad.E1A(+) at a V/T ratio of 200 : 1 had the maximum downregulating eect on the HER-2/neu-encoded protein product (p185), as determined by Western blot analysis with the Ab-3 anti-HER-2/neu antibody ( Figure 3 ). There was no downregulation of p185 in cells treated with Ad.E1A(7) (data not shown). There was also no dierence in the patterns of downregulation induced by either the serum-depleted or regular infection protocol. The degree of downregulation of p185 was similar in both MDA-MB-361 and MDA-MB-453 cells (data not shown). When the two breast cancer cell lines with basal levels of HER-2/neu expression, MDA-MB-435 and MDA-MB-231, were exposed to Ad.E1A(+) at a 400 : 1 V/T ratio, the E1A expression level was comparable to that of MDA-MB-453 cells infected at a 200 : 1 V/T ratio (data not shown). There was also no dierence in HER-2/neu expression levels which is consistent to the previous publication (Frisch and Dolter, 1995; Yan et al., 1991; Yu et al., 1993b) . We noticed that down-regulation of HER-2/neu by E1A is more profound in HER-2/neuoverexpressing cancer cells than the cancer cells with basal level of HER-2/neu expression.
Sensitization of HER-2/neu-overexpressing breast cancer cells to paclitaxel by E1A
Once the correlation of E1A expression and p185 repression was established in the HER-2/neu-overexpressing human breast cancer cells, an MTT assay was conducted to test whether the E1A gene could sensitize HER-2/neu-overexpressing human breast cancer cells to paclitaxel. Adenoviral vectors were applied to the cells for 48 h and then various concentrations of paclitaxel (from 0.01 to 100 mM) were applied ( Figure 4 ). As controls, Ad.E1A (7) alone, Ad.E1A(7) plus paclitaxel, paclitaxel alone, and Ad.E1A(+) alone were also prepared and applied to cells; their eects were compared with those of Ad.E1A(+) plus paclitaxel. Signi®cant synergistic growth inhibition of the viable fraction of MDA-MB-453 cells was reached when Ad.E1A(+) (V/T ratio of 200 : 1) plus paclitaxel (0.01 ± 10 mM) was applied ( Figure 5a ). The criterion for a synergistic eect was a combined eect less than 70% of the value predicted for single agents (see Materials and methods). There was no dierence in the inhibition of cell viability between paclitaxel alone and Ad.E1A(7) plus paclitaxel as above. In the analysis of the eect of paclitaxel over time, sensitization to paclitaxel by Ad.E1A(+) in the HER-2/neu-overexpressing cells MDA-MB-453 was initially observed around day 2 and became much more signi®cant on days 3 and 4 after treatment with paclitaxel (data not shown). However, the low HER-2/neu-expressing MDA-MB-435 cells were sensitive to treatment with paclitaxel alone. Neither Ad.E1A(+) nor Ad.E1A (7) infection further enhanced the sensivitiy of the low HER-2/neuexpressing cells to paclitaxel (data not shown). A In general, anchorage-independent growth in soft agar represents an in vitro transformation phenotype that is highly correlated with in vivo tumorigenicity. As shown in Figure 6 , Ad.E1A(+) alone suppressed the colonies to 35% when compared with untreated cells, and paclitaxel alone reduced the colonies to 17%. When Ad.E1A(+) and paclitaxel were given together, there were almost no viable colonies (P50.001). A signi®cant synergistic growth inhibition of soft agar colonization was observed in the HER-2/neu-overexpressing MDA-MB-453 cells, but not in the low-HER-2/neu-expressing MDA-MB-435 cells. Taken together, these results indicate that Ad.E1A(+) can sensitize the response of HER-2/neu-overexpressing human breast cancer cells to paclitaxel and that the synergistic eect is likely due to downregulation of HER-2/neu by the E1A gene product.
Discussion
Results from our present study of paclitaxel-treated stable transfectants of mouse embryo ®broblasts having the same genetic background but expressing Figure 4 Dosing schedule for combined E1A gene therapy and paclitaxel chemotherapy. Breast cancer cells were plated into a 96-well plate. After attachment of cells was con®rmed, adenoviral vectors were delivered under the serum-depleted or regular infection protocol for 2 days, and the cells were exposed to various concentrations of paclitaxel. The viability of cells was then monitored by MTT assay or direct cell counting up to 4 days after paclitaxel treatment dierent levels of HER-2/neu strongly suggest that paclitaxel sensitivity is HER-2/neu dependent. Moreover, treatment of HER-2/neu overexpressing human breast cancer cell lines with both paclitaxel and an adenoviral vector that allows transient expression of E1A produced a strong synergistic eect. In addition, there appears to be no correlation between paclitaxel resistance and the expression of other human epidermal growth factor receptors such as EGFR, HER-3 and HER-4 in the breast cancer cells we studied. EGFR is expressed intermediately in MDA-MB-231 (Davidson et al., 1987) , and at low level in MDA-MB-453, MDA-MB-361 cells (Kraus et al., 1987) , and MDA-MB-435 cells (unpublished data). HER-3 is highly expressed in MDA-MB-453 and MDA-MB-361 cells (Alimandi et al., 1995) , intermediately in MDA-MB-231 cells, and weakly in MDA-MB-435 cells (unpublished data). HER-4 is expressed highly in MDA-MB-453 cells, intermediately in MDA-MB-361 cells, and undetectable in MDA-MB-231 cells (Plowman et al., 1993; Tzahar et al., 1994) . HER-4 expression in MDA-MB-435 cells is not known. Overall, our results suggest that by targeting HER-2/ neu and downregulating its expression, E1A can modify cell sensitivity to paclitaxel. This in turn may have potential for future clinical application.
Recently, it was reported that E1A can sensitize cancer cell lines that do not overexpress HER-2/neu to chemotherapeutic agents. One group has reported sensitization to the alkylating agent cisplatin due to p53-dependent apoptosis induced by E1A (Lowe et al., 1993) . Other groups have reported sensitization to cisplatin via a p53-independent mechanism (Sanchezprieto et al., 1996) . In our present study, p53 gene was mutated or lost in all four cancer cell lines we studied: MDA-MB-453 (Runnenbaum et al., 1991) , MDA-MB-435 (Lesoon-Wood et al., 1995) , MDA-MB-361 (in which is chromosome 17 deleted and p53 is not detected by Western blotting), and MDA-MB-231 (Runnenbaum et al., 1991) . Another group has reported the sensitization to cisplatin and VP-16 by E1A of low-HER-2/neu-expressing cancer cell lines (Frisch and Dolter, 1995) . It should be pointed out that HER-2/neu overexpression in breast cancer cells confers resistance to paclitaxel but not to cisplatin (unpublished data). In the current study, downregulation of HER-2/neu expression was critical for E1A sensitization to paclitaxel, whereas other studies used DNA-damaging agents that may involve dierent mechanisms of action.
HER-2/neu overexpression in breast cancer patients is a poor prognostic factor (Gusterson et al., 1992; McCann et al., 1991; Slamon et al., 1987 Slamon et al., , 1989 Toikkanen et al., 1992; van de Vijver et al., 1987) . In addition, both clinical trials and laboratory research have strongly suggested that HER-2/neu overexpression may be a chemotherapeutic resistance marker in breast cancers (Gusterson et al., 1992; Tsai et al., 1994 Tsai et al., , 1995 . The current study clearly demonstrates that downregulation of HER-2/neu by E1A, which is known to downregulate HER-2/neu overexpression (Yan et al., 1991; Yu et al., 1992 Yu et al., , 1994a Yu et al., , 1993b , forces HER-2/neu-overexpressing human breast cancer cells originally resistant to paclitaxel to become sensitive. We have previously shown that E1A is a strong tumor suppressor of HER-2/neu-overexpressing cancers in vivo (Chang et al., 1996; Yu et al., 1995; Zhang et al., 1995) . Based on our previous results, an E1A gene therapy clinical trial in humans has recently been initiated at our institution, in which the E1A gene is delivered to the thoracic or peritoneal cavity of patients who have HER-2/neuoverexpressing breast or ovarian cancer. The current study suggests a way to further develop novel therapeutic approaches for HER-2/neu-overexpressing cancers by combining E1A gene therapy with paclitaxel chemotherapy. Although this new concept needs to be rigorously tested in animal model, we hope that it may provide patients with HER-2/neu-overexpressing cancers a greater therapeutic bene®t.
Materials and methods
Cell lines and culture conditions
Human breast cancer cell lines MDA-MB-435, MDA-MB-453, MDA-MB-361, and MDA-MB-231 were obtained from the American Type Culture Collection (ATCC) (Miller and Hung, 1995) . All cell lines were grown in DMEM/F12 medium (GIBCO, Grand Island, NY) supplemented with 10% FBS and penicillin/streptomycin. Cells were grown in a humidi®ed incubator at 378C under 5% CO 2 in air.
Recombinant adenovirus
Recombinant replication-de®cient adenoviral vectors were propagated in 293 cells as previously described (Zhang et al., 1995) . Cells were harvested 48 h after infection, pelleted, resuspended in PBS, and lysed; cell debris was removed by subjecting the cells to CsCl gradient puri®cation. The concentrated virus was then dialyzed, aliquoted, and stored at 7808C. Virus titration was performed as previously described (Liu et al., , 1995 . In brief, 25 ml of virus sample was mixed with 465 ml of PBS and 10 ml of 5% SDS. After centrifugation, the supernatant, which contains viral DNA, was measured for OD at a wavelength of 260 nm. The titer based on OD was about three times higher than the actual PFU (data not shown). One OD unit equals about 10 12 particles per ml. Three types of adenoviral vector were used: Ad.E1A(+) dl324 (Yan et al., 1991) , an adenovirus type 5 containing E1A but lacking E1B and E3; control vector Ad.E1A (7) dl312 (Jones and Shenk, 1979) , containing E1B but lacking E1A and E3; and Ad.RSVlacZ, an adenovirus type 5-based vector lacking E1A, E1B, and E3 but containing the Rous sarcoma virus-long terminal repeat as a promoter driving the Escherichia coli lacZ gene (Stratford et al., 1992) .
Two types of infection protocols were carried out. On the regular infection protocol, we applied the adenoviral vectors to target cells plated in DMEM/F12 and 10% FBS. However, we noticed that the infection eciency in the presence of 10% FBS was always lower for the low-HER-2/ neu-expressing lines MDA-MB-435 and MDA-MB-231 than for the overexpressing lines MDA-MB-453 and MDA-MB-361. Therefore, to increase the infection eciency of adenoviral vectors for the low-HER-2/neu-expressing cells, we used a serum-depletion infection protocol. We plated the cells in DMEM/F12 with 10% FBS for 12 ± 18 h and then replaced the serum-containing medium with DMEM/F12 alone. The adenoviral vectors in DMEM/F12 were then incubated with the cells for 48 h. The serum-depletion infection protocol allowed comparable infection eciencies to be obtained for all cell lines tested in this study.
Infection eciency assay
Cells were plated (10 ± 30610 4 /well) in six-well culture plates. We infected the cells with Ad.RSVlacZ at dierent V/T ratios. Two days later, cells were ®xed with 2% formaldehyde and 0.2% glutaraldehyde in PBS at 48C for 5 min, washed with PBS, and then stained with 1 mg/ml Xgal in 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, and 2 mM MgCl 2 in PBS at 378C overnight. Infection eciency was calculated as one positive cell/ number of total cells6100%.
Western blot analysis
As described previously (Kiyokawa et al., 1995; Matin et al., 1990) , cells were washed three times with PBS and then lysed in lysis buer (20 mM Na 2 PO 4 , pH 7.4, 150 mM NaCl, 1% Triton X-100, 1% aprotinin, 1 mM phenylmethylsulfonyl¯uoride, 100 mM NaF, and 2 mM Na 3 VO 4 ). Protein content was determined against a standardized control using the Bio-Rad protein assay kit (Bio-Rad Laboratories, Hercules, CA). A total of 50 mg of protein was separated by 8% SDS ± PAGE and transferred to nitrocellulose ®lter paper (Schleicher and Schuell, Inc., Keene, NH). Nonspeci®c binding on the nitrocellulose ®lter paper was minimized with a blocking buer containing nonfat dry milk (5%) and Tween 20 (0.1%, v/v) in PBS. The treated ®lter paper was incubated ®rst with the primary antibodies anti-HER-2/neu antibody c-neu (Ab-3) (Oncogene Science, Uniondale, NY) and anti-adenovirus type 5 E1A antibody m58 (Pharmingen, San Diego, CA) and then with HRPgoat anti-mouse antibody (1 : 1000 dilution) (BoehringerMannheim Corp., Indianapolis, IN). Equal loading of protein was con®rmed by probing the same SDS ± PAGE gel with the anti-actin antibody N350 (Amersham Corp., Arlington, IL). Protein bands were visualized using an enhanced chemiluminescence system (Amersham Corp., Arlington Heights, IL).
Paclitaxel
A stock solution of paclitaxel (Bristol-Meyers Squibb Co., Wallingford, CT) was stored at 7808C until used. Paclitaxel was dissolved in DMEM/F12 before it was used.
Drug sensitivity assays
Cells were detached by trypsinization, seeded at 1.0 ± 2.0610 3 cells/well in a 96-well microtiter plate overnight, and infected with adenoviral vectors. Forty-eight hours later, the cells were treated with various concentrations of paclitaxel in DMEM/F12 with 10% FBS. The eects on cell growth were examined by MTT assay. In brief, 20 ml of MTT solution (5 mg/ml in PBS) (Sigma Chemical Co., St. Louis, MO) was added to each well and incubated for 2 h at 378C. The MTT formazan formed by metabolically viable cells was dissolved in 100 ml of cell-lysing buer, and uorescence was monitored by a microplate reader (Dynatech MR 5000¯uorescence; Dynatech Corp., Burlington, MA) at a wavelength of 570 nm (Hansen et al., 1989) .
Growth rates
Cells were plated at a density of 30610 4 /well in six-well culture plates in quadruplicate. Cells were infected with adenoviral vectors for 48 and exposed to paclitaxel (10 mM). Cells were trypsinized so that their viability could be determined by trypan blue staining.
Soft agar colony-formation assays
As previously described (Zhang et al., 1995) , 20 ± 40610 4 cells/well were plated in six-well culture plates, treated with adenoviral vectors for 48 h and exposed to paclitaxel. The cells (2610 3 /well) were inoculated into soft agar (0.35% SeaPlaque; FMC Bioproducts, Rockland, ME), in DMEM/F12 in quadruplicate. The agar was then plated over a base layer of 0.7% agarose in 24-well plates and incubated for a maximum of 6 weeks. The plates were then stained with p-iodonitrotetrazolium violet (1 mg/ml) for 48 h at 378C. The colonies of greater than 50 cells that formed were counted.
Evaluation of synergistic eect
As previously de®ned (Hata et al., 1994; Webb, 1963; Zhang and Hung, 1996) , a synergistic eect occurred whenever the combined eect of E1A and paclitaxel on cell growth was less than 70% of predicted values. Predicted values was calculated from the equation c=a6b/100, where a and b are the values for viable cells treated with single agents and c is the predicted value.
Abbreviations DMEM/F12, Dulbecco's modi®ed Eagle's medium/Ham's F12; FBS, fetal bovine serum; PBS, phosphate-buered saline; SDS, sodium dodecyl sulfate; PAGE, polyacrylamide gel electrophoresis; OD, optical density; MTT, (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; PFU, plaque-forming unit; V/T, virus/tumor cell.
